Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT03252431 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

393

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Neutropenia

Interventions

DRUG: F-627
DRUG: Neulasta

Sponsor

EVIVE Biotechnology